Cisplatin Linked to Cardiac Complications in Testicular Ca Patients
Long-term survivors of testicular cancer treated with cisplatin-based chemotherapy have evidence of endothelial injury and dysfunction, compared with those who did not receive chemotherapy, according to a University of Pennsylvania study (Cancer 112:1949-1953, 2008).
Long-term survivors of testicular cancer treated with cisplatin-based chemotherapy have evidence of endothelial injury and dysfunction, compared with those who did not receive chemotherapy, according to a University of Pennsylvania study (Cancer 112:1949-1953, 2008). In the cross-sectional study, David J. Vaughn , MD, and colleagues assessed cardiovascular risk, subclinical atherosclerosis, and endothelial function in 24 long-term survivors. The cisplatin patients had reduced mean brachial artery flow-mediated dilatation and significantly higher mean soluble intercellular adhesion molecule-1 (SICAM-1) levels. Dr. Vaughn suggested that biomarkers of endothelial dysfunction could potentially identify asymptomatic long-term testicular cancer survivors who are at increased risk of cardiovascular events.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Evaluation and Management of Testicular Cancer After Late Relapse
The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.
